AlzeCure Pharma AB (FRA:AC6) Land And Improvements : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is AlzeCure Pharma AB Land And Improvements?

AlzeCure Pharma AB's land and improvements for the quarter that ended in Mar. 2025 was €0.00 Mil.

AlzeCure Pharma AB Land And Improvements Historical Data

The historical data trend for AlzeCure Pharma AB's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB Land And Improvements Chart

AlzeCure Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

AlzeCure Pharma AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

AlzeCure Pharma AB Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

AlzeCure Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (FRA:AC6) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

ALZCUR:Sweden

Address

Halsovagen 7, Huddinge, SWE, SE 141 57

Website

https://www.alzecurepharma.se

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatments of severe pain in conditions such as osteoarthritis.

AlzeCure Pharma AB Headlines

No Headlines